Divi’s Laboratory share price hits high in 52-week post Q2 profit jump of 45.63%
On the account of robust sales, the drug firm Divi's Laboratory reported a rise in consolidated net profit of 45.63 percent to Rs. 519.59 crore for the second quarter.
Stay updated with the latest news and articles about Companies.
On the account of robust sales, the drug firm Divi's Laboratory reported a rise in consolidated net profit of 45.63 percent to Rs. 519.59 crore for the second quarter.
Earnings before interest, tax, depreciation and amortizations (EBITDA) was down 7.5 percent at Rs 98 crore versus Rs 106 crore and the margin was down 6.1 percent versus 7.4 percent, YoY.
Raja Pullan said, “Samsung’s overall consumer electronics sales grew an annual 20 percent in August and September after India’s economy began to open up.”
Axis Capital, ICICI Securities, Citigroup Global Markets India and SBI Capital Markets are the global co-ordinators and book running lead managers to the offer.
Showing 79 of 79 articles